<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068207</url>
  </required_header>
  <id_info>
    <org_study_id>5010-MINO-RP</org_study_id>
    <nct_id>NCT04068207</nct_id>
  </id_info>
  <brief_title>Minocycline Treatment in Retinitis Pigmentosa</brief_title>
  <official_title>The Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d),
      administered for 6 months, for the treatment of patients with retinitis pigments(RP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinitis Pigmentosa (RP)is a sort of inherited blinding disorders and no effective or safe
      treatment are widely applied for it. The worldwide prevalence of RP is estimated to be
      1/5000. RP is characterized by degeneration of peripheral rod photoreceptor(PR) and
      associated retinal pigment epithelium(RPE) cells. Nyctalopia and visual field constriction
      are common symptoms. Cone degeneration and associated loss of central vision are typically
      followed later.

      Minocycline, a secord-generation, semi-synthetic tetracycline antibiotic, is a highly
      lipophilic molecule and can easily pass through the blood-brain barrier. Several animal
      experiments and clinical trials have reported that minocycline exert anti-apoptotic,
      anti-inflammatory and antioxidant effects in treating neurodegenerative diseases.

      We propose to test the effect and safety of oral minocycline for retinitis pigmentosa.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 22, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of full-field cone electroretinogram amplitude to 30-Hz flashes</measure>
    <time_frame>24 weeks</time_frame>
    <description>increase of full-field cone electroretinogram amplitude to 30-Hz flashes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of visual field area</measure>
    <time_frame>24 weeks</time_frame>
    <description>HFA30-2 and HFA60-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>24 weeks</time_frame>
    <description>increase of BCVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central foveal thickness</measure>
    <time_frame>24 weeks</time_frame>
    <description>increase of central foveal thickness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Inherited Retinal Dystrophy</condition>
  <condition>Retina Disorder</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets Minocycline 100mg po per day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Tab. Minocycline 100mg po per day for 24 weeks</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Minocin</other_name>
    <other_name>Minocyclinum</other_name>
    <other_name>Minocyclin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Retinitis Pigmentosa: nyctalopia, visual field constriction and
             loss of central vision; degeneration of peripheral rod photoreceptor and retinal
             pigment epithelium cells.

          -  Age from 18 to 60 years old.

          -  BCVA &gt;20/100(0.2).

          -  Full-field cone electroretinogram amplitude to 30-Hz flashes &gt;0uV.

          -  Written informed consent is provided.

        Exclusion Criteria:

          -  Glucocortticoids or tetracycline were used within 3 months.

          -  Vitamin A, DHA and other neurotrophic drugs were used within 3 months.

          -  Other ocular diseases or fundus diseases except cataract: glaucoma, diabetic
             retinopathy, retinal detachment.

          -  Tetracycline or minocycline allergy or intolerance.

          -  Renal or hepatic insufficiency.

          -  History of thyroid neoplasm.

          -  History of idiopathic intracranial hypertension.

          -  Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Liang, MD</last_name>
    <phone>0086-20-87330402</phone>
    <email>liangd2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liang, MD</last_name>
      <phone>0086-20-87330402</phone>
      <email>liangd2@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Dan Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liang</last_name>
      <phone>0086-20-87330402</phone>
      <email>liangd2@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Dan Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dan Liang</investigator_full_name>
    <investigator_title>Lab of ocular immunology in Zhongshan Ophthalmic Center</investigator_title>
  </responsible_party>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Minocycline</keyword>
  <keyword>ERG</keyword>
  <keyword>Inherited Retinal Dystrophy</keyword>
  <keyword>Retinal Degenerative Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

